Chengdu Shengnuo Biopharm Co.ltd.

  Chengdu Shengnuo Tech Co.,Ltd was founded in DaYi, within the city of Chengdu in July, 2001, The registered capital is 

      50 million RMB and has 3 subsidiaries: Chengdu Shengnuo Biopharm Co,Ltd, Chengdu Shengnuo Chemicals Co.,Ltd and Chengdu   Shengnuo Trade Co.,Ltd. Since the inception, our annual revenue has gone from 1 million toover 150 million. With a Chengdu City  approved research center, “Chengdu Engineering R&D Center of Peptide Drug” and with the recent approval as a registered US FDA  manufacturing facility with zero 483 citations, we are a leading contract manufacturer of peptides by solid-phase chemistry  within the domestic market.   
      We are a participant in National “11-5” new drugs creation project “the key technology research of  peptide chemistry modification and industrial scale             preparation”. We also have received National  Funding from the National SME Technology Innovation Fund for the cardiovascular drug – Nesiritide.  With further access to the Sichuan Province Government Specialty Fund, we receive research support toindustrialize the manufacturing of solid-phase peptidebased drugs. We now have over 50 key  technologies for large-scale production ofdomestic and foreign peptide drugs, the ability to  produce singlemulti-kilogram batch quantities of several difficult peptide sequences,including  sulfur cycle peptides, complex carbon ring peptides, and rapidsynthesis technologies etc. With o ver 20+ patents filed in the peptide fieldand several inventor patents, this further confirms  our role as the industryleader in domestic polypeptide market.                                     The company founder, Yongjun Wen was previously the Production Head ofthe first R&D and  Commercial Production Team in China, managing the first peptide drug thymopentin which generates  annual sales of over 500 million. Mr.Wen also has maintained his commitment to supporting the  Academic Community with a significant amount of collaborations, including: The University of  Sichuan, The University of Lanzhou, The University of Jilin, Chinese Academy of Engineering,  Institute of Organic Chemistry, Provincial Institute for Drug Control etc. Shengnuo also has  many commercial partners, which include: Chengdu DIAO Group, Zhengjiang Hisun Group, Harbin  Pharmacetuical Group,Hainan Zhonghe Pharmacetuical Co., Ltd., etc.                      Shengnuo also has partnerships with foreign companies both in theUnited States and India.  By sharing key technologies and transferring trainingand production guidance, we are able to keep  in touch with internationallyrecognized Peptide Research Institutes in order to constantly stay up  to dateon all new technologies.         With the support of both the state and national government, Shengnuo has had the opportunity  to develop several peptide based drug substances in the last decade. With this, we strive to continue  to be the best and largest manufacturer of peptide drugs for both the Chinese and International market.